Anti-COVID-19 Vaccination in Patients with Autoimmune-Autoinflammatory Disorders and Primary/Secondary Immunodeficiencies: The Position of the Task Force on Behalf of the Italian Immunological Societies

Clinical management of patients with primary immunodeficiencies during the COVID-19 pandemic

(2021) Isabella Quinti et al.   Expert Review of Clinical Immunology

Immunogenicity of Viral Vaccines in the Italian Military

(2021) Claudia Ferlito et al.   Biomedicines

Thrombocytopenia following Pfizer and Moderna SARS‐CoV ‐2 vaccination

(2021) Eun‐Ju Lee et al.   AMERICAN JOURNAL OF HEMATOLOGY

EULAR December 2020 viewpoints on SARS-CoV-2 vaccination in patients with RMDs

(2021) Johannes WJ Bijlsma   ANNALS OF THE RHEUMATIC DISEASES

Immunogenicity of the Ad26.COV2.S Vaccine for COVID-19

(2021) Kathryn E. Stephenson et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia

(2021) Denis Y Logunov et al.   LANCET

Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: interim results from a double-blind, randomised, multicentre, phase 2 trial, and 3-month follow-up of a double-blind, randomised phase 1 trial

(2021) Raches Ella et al.   LANCET INFECTIOUS DISEASES

Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies

(2021) Dami A. Collier et al.   NATURE

Serum Neutralizing Activity Elicited by mRNA-1273 Vaccine — Preliminary Report

(2021) Kai Wu et al.   NEW ENGLAND JOURNAL OF MEDICINE

Neutralizing Activity of BNT162b2-Elicited Serum

(2021) Yang Liu et al.   NEW ENGLAND JOURNAL OF MEDICINE

Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England

(2021) Nicholas G. Davies et al.   SCIENCE

Immunogenicity and protective efficacy of inactivated SARS-CoV-2 vaccine candidate, BBV152 in rhesus macaques

(2021) Pragya D. Yadav et al.   Nature Communications

Heterologous prime-boost: Breaking the protective immune response bottleneck of COVID-19 vaccine candidates

(2021) Qian He et al.   Emerging Microbes & Infections

Seroconversion Following COVID-19 Vaccination in Immune Deficient Patients

(2021) Jacqueline Squire et al.   ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY

Safety of the first dose of mRNA SARS-CoV-2 vaccines in patients with rheumatic and musculoskeletal diseases

(2021) Caoilfhionn M Connolly et al.   ANNALS OF THE RHEUMATIC DISEASES

SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response

(2021) Michael Markus Bonelli et al.   ANNALS OF THE RHEUMATIC DISEASES

SARS-CoV-2 vaccination responses in untreated, conventionally treated and anticytokine-treated patients with immune-mediated inflammatory diseases

(2021) David Simon et al.   ANNALS OF THE RHEUMATIC DISEASES

Rituximab, but not other antirheumatic therapies, is associated with impaired serological response to SARS- CoV-2 vaccination in patients with rheumatic diseases

(2021) Robert Spiera et al.   ANNALS OF THE RHEUMATIC DISEASES

Immunogenicity and safety of anti-SARS-CoV-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort

(2021) Ulf M Geisen et al.   ANNALS OF THE RHEUMATIC DISEASES

Antibody evasion by the P.1 strain of SARS-CoV-2

(2021) Wanwisa Dejnirattisai et al.   CELL

SARS-CoV-2–Specific Antibodies in Breast Milk After COVID-19 Vaccination of Breastfeeding Women

(2021) Sivan Haia Perl et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Antibody Response to 2-Dose SARS-CoV-2 mRNA Vaccine Series in Solid Organ Transplant Recipients

(2021) Brian J. Boyarsky et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

US Case Reports of Cerebral Venous Sinus Thrombosis With Thrombocytopenia After Ad26.COV2.S Vaccination, March 2 to April 21, 2021

(2021) Isaac See et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Immunogenicity of COVID-19 mRNA Vaccines in Pregnant and Lactating Women

(2021) Ai-ris Y. Collier et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

COVID-19 Vaccines vs Variants—Determining How Much Immunity Is Enough

(2021) Rita Rubin   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Heterologous prime-boost COVID-19 vaccination: initial reactogenicity data

(2021) Robert H Shaw et al.   LANCET

Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study

(2021) Leticia Monin et al.   LANCET ONCOLOGY

Mix-and-match COVID vaccines trigger potent immune response

(2021) Ewen Callaway   NATURE

Increased mortality in community-tested cases of SARS-CoV-2 lineage B.1.1.7

(2021) Nicholas G. Davies et al.   NATURE

Preliminary Findings of mRNA Covid-19 Vaccine Safety in Pregnant Persons

(2021) Tom T. Shimabukuro et al.   NEW ENGLAND JOURNAL OF MEDICINE

Effectiveness of the BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 Variants

(2021) Laith J. Abu-Raddad et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pathologic Antibodies to Platelet Factor 4 after ChAdOx1 nCoV-19 Vaccination

(2021) Marie Scully et al.   NEW ENGLAND JOURNAL OF MEDICINE

Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant

(2021) Shabir A. Madhi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19

(2021) Jerald Sadoff et al.   NEW ENGLAND JOURNAL OF MEDICINE

Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant

(2021) Vivek Shinde et al.   NEW ENGLAND JOURNAL OF MEDICINE

Herpes zoster following BNT162b2 mRNA Covid-19 vaccination in patients with autoimmune inflammatory rheumatic diseases: a case series

(2021) Victoria Furer et al.   RHEUMATOLOGY

mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection

(2021) Leonidas Stamatatos et al.   SCIENCE

Genomics and epidemiology of the P.1 SARS-CoV-2 lineage in Manaus, Brazil

(2021) Nuno R. Faria et al.   SCIENCE

Heterologous vaccination regimens with self-amplifying RNA and adenoviral COVID vaccines induce robust immune responses in mice

(2021) Alexandra J. Spencer et al.   Nature Communications

Neutralizing antibody responses to SARS-CoV-2 in symptomatic COVID-19 is persistent and critical for survival

(2021) Stefania Dispinseri et al.   Nature Communications

Operation Warp Speed: implications for global vaccine security

(2021) Jerome H Kim et al.   Lancet Global Health

How to Manage COVID-19 Vaccination in Immune-Mediated Inflammatory Diseases: An Expert Opinion by IMIDs Study Group

(2021) Francesca Ferretti et al.   Frontiers in Immunology

Correspondence on ‘SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response’

(2021) Timm H Westhoff et al.   ANNALS OF THE RHEUMATIC DISEASES

LB0003 IMMUNOGENICITY AND SAFETY OF THE BNT162b2 mRNA COVID-19 VACCINE IN ADULT PATIENTS WITH AUTOIMMUNE INFLAMMATORY RHEUMATIC DISEASES AND GENERAL POPULATION: A MULTICENTER STUDY

(2021) V. Furer et al.   ANNALS OF THE RHEUMATIC DISEASES

Successful BNT162b2 booster vaccinations in a patient with rheumatoid arthritis and initially negative antibody response

(2021) Fredrik N Albach et al.   ANNALS OF THE RHEUMATIC DISEASES

High antibody response to two-dose SARS-CoV-2 messenger RNA vaccination in patients with rheumatic and musculoskeletal diseases

(2021) Jake A Ruddy et al.   ANNALS OF THE RHEUMATIC DISEASES

Methotrexate hampers immunogenicity to BNT162b2 mRNA COVID-19 vaccine in immune-mediated inflammatory disease

(2021) Rebecca H Haberman et al.   ANNALS OF THE RHEUMATIC DISEASES

Seroconversion rates following COVID-19 vaccination among patients with cancer

(2021) Astha Thakkar et al.   CANCER CELL

Immunogenicity of Pfizer-BioNTech COVID-19 vaccine in patients with inborn errors of immunity

(2021) David Hagin et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness

(2021) Aziz Sheikh et al.   LANCET

Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey

(2021) Mine Durusu Tanriover et al.   LANCET

Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents: a double-blind, randomised, controlled, phase 1/2 clinical trial

(2021) Bihua Han et al.   LANCET INFECTIOUS DISEASES

Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection

(2021) Zijun Wang et al.   NATURE

Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant

(2021) Jamie Lopez Bernal et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents

(2021) Robert W. Frenck et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine

(2021) Paul T. Heath et al.   NEW ENGLAND JOURNAL OF MEDICINE

Three Doses of an mRNA Covid-19 Vaccine in Solid-Organ Transplant Recipients

(2021) Nassim Kamar et al.   NEW ENGLAND JOURNAL OF MEDICINE

Heterologous ChAdOx1 nCoV-19 and mRNA-1273 Vaccination

(2021) Johan Normark et al.   NEW ENGLAND JOURNAL OF MEDICINE

Prevention and Attenuation of Covid-19 with the BNT162b2 and mRNA-1273 Vaccines

(2021) Mark G. Thompson et al.   NEW ENGLAND JOURNAL OF MEDICINE

American College of Rheumatology Guidance for COVID‐19 Vaccination in Patients With Rheumatic and Musculoskeletal Diseases: Version 2

(2021) Jeffrey R. Curtis et al.   Arthritis & Rheumatology

Safety, reactogenicity, and immunogenicity of homologous and heterologous prime-boost immunisation with ChAdOx1 nCoV-19 and BNT162b2: a prospective cohort study

(2021) David Hillus et al.   Lancet Respiratory Medicine

The Safety and Immunogenicity of the mRNA-BNT162b2 SARS-CoV-2 Vaccine in Hemodialysis Patients

(2021) Emanuel Zitt et al.   Frontiers in Immunology

Myocarditis Following Immunization With mRNA COVID-19 Vaccines in Members of the US Military

(2021) Jay Montgomery et al.   JAMA Cardiology

Myocarditis following COVID-19 vaccination

(2021) Elisabeth Albert et al.   Radiology Case Reports

Currently available intravenous immunoglobulin contains antibodies reacting against severe acute respiratory syndrome coronavirus 2 antigens

(2020) José-María Díez et al.   Immunotherapy

A possible role for B cells in COVID-19? Lesson from patients with agammaglobulinemia

(2020) Isabella Quinti et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial

(2020) Feng-Cai Zhu et al.   LANCET

The pandemic pipeline

(2020) John Hodgson   NATURE BIOTECHNOLOGY

ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques

(2020) Neeltje van Doremalen et al.   NATURE

Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates

(2020) Kizzmekia S. Corbett et al.   NEW ENGLAND JOURNAL OF MEDICINE

Prevalence and clinical outcomes of COVID-19 in patients with autoimmune diseases: a systematic review and meta-analysis

(2020) Shintaro Akiyama et al.   ANNALS OF THE RHEUMATIC DISEASES

Vaccines for COVID‐19

(2020) J. S. Tregoning et al.   CLINICAL AND EXPERIMENTAL IMMUNOLOGY

Coronavirus disease 2019 in patients with inborn errors of immunity: An international study

(2020) Isabelle Meyts et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia

(2020) Denis Y Logunov et al.   LANCET

Phase 1–2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine

(2020) Cheryl Keech et al.   NEW ENGLAND JOURNAL OF MEDICINE

NVX-CoV2373 vaccine protects cynomolgus macaque upper and lower airways against SARS-CoV-2 challenge

(2020) Mimi Guebre-Xabier et al.   VACCINE

The risk for severe COVID 19 in patients with autoimmune and/or inflammatory diseases: First wave lessons

(2020) Amit Druyan et al.   Dermatologic Therapy

COVID-19 in patients with primary and secondary immunodeficiency: The United Kingdom experience

(2020) Adrian M. Shields et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

(2020) Merryn Voysey et al.   LANCET

Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial

(2020) Maheshi N Ramasamy et al.   LANCET

Persistence and Evolution of SARS-CoV-2 in an Immunocompromised Host

(2020) Bina Choi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine

(2020) Lindsey R. Baden et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

(2020) Fernando P. Polack et al.   NEW ENGLAND JOURNAL OF MEDICINE

Maintaining Safety with SARS-CoV-2 Vaccines

(2020) Mariana C. Castells et al.   NEW ENGLAND JOURNAL OF MEDICINE

Enhanced SARS-CoV-2 neutralization by dimeric IgA

(2020) Zijun Wang et al.   Science Translational Medicine

Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial

(2020) Yanjun Zhang et al.   LANCET INFECTIOUS DISEASES

2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases

(2019) Victoria Furer et al.   ANNALS OF THE RHEUMATIC DISEASES

Vaccination in Multiple Sclerosis: Friend or Foe?

(2019) Tobias Zrzavy et al.   Frontiers in Immunology

Anti-polysaccharide and anti-diphtheria protective antibodies after 13-valent pneumococcal conjugate vaccination in rheumatoid arthritis patients under immunosuppressive therapy

(2018) Sara Caporuscio et al.   CLINICAL IMMUNOLOGY

Vaccination in immunocompromised host: Recommendations of Italian Primary Immunodeficiency Network Centers (IPINET)

(2018) Baldassarre Martire et al.   VACCINE

Lymphopenia and risk of infection and infection-related death in 98,344 individuals from a prospective Danish population-based study

(2018) Marie Warny et al.   PLOS MEDICINE

Lupus érythémateux systémique et lymphopénie : aspects cliniques et physiopathologiques

(2017) M. Martin et al.   REVUE DE MEDECINE INTERNE

Safety of live vaccinations on immunosuppressive therapy in patients with immune-mediated inflammatory diseases, solid organ transplantation or after bone-marrow transplantation – A systematic review of randomized trials, observational studies and case reports

(2017) Evelina Croce et al.   VACCINE

Memory T cell responses targeting the SARS coronavirus persist up to 11 years post-infection

(2016) Oi-Wing Ng et al.   VACCINE

Prime-boost vaccine strategy against viral infections: Mechanisms and benefits

(2016) Kimia Kardani et al.   VACCINE

Vaccination in patients with primary immune deficiency, secondary immune deficiency and autoimmunity with immune regulatory abnormalities

(2015) Martha M Eibl et al.   Immunotherapy

Leukopenia, lymphopenia, and neutropenia in systemic lupus erythematosus: Prevalence and clinical impact—A systematic literature review

(2015) Linda Carli et al.   SEMINARS IN ARTHRITIS AND RHEUMATISM

Executive Summary: 2013 IDSA Clinical Practice Guideline for Vaccination of the Immunocompromised Host

(2014) Lorry G. Rubin et al.   CLINICAL INFECTIOUS DISEASES

Infection risk in Rheumatoid Arthritis and Spondyloarthropathy patients under treatment with DMARDs, Corticosteroids and TNF-α antagonists

(2014) Valentina Germano et al.   Journal of Translational Medicine

The cellular immune response to influenza vaccination is preserved in rheumatoid arthritis patients treated with rituximab

(2011) U. Arad et al.   VACCINE

Are Anti-Infectious Vaccinations Safe and Effective in Patients with Autoimmunity?

(2010) Simonetta Salemi et al.   INTERNATIONAL REVIEWS OF IMMUNOLOGY